IRIS - Res&Arch Institutional Research Information System - Research & Archive

BOLLI, Geremia Brunetto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.218
NA - Nord America 4.156
AS - Asia 1.032
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 3
AF - Africa 1
Totale 9.422
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.144
UA - Ucraina 1.080
IE - Irlanda 830
SE - Svezia 731
IT - Italia 478
SG - Singapore 296
FI - Finlandia 257
HK - Hong Kong 247
RU - Federazione Russa 215
DE - Germania 212
VN - Vietnam 192
FR - Francia 165
CN - Cina 148
TR - Turchia 112
GB - Regno Unito 104
AT - Austria 34
CH - Svizzera 29
CZ - Repubblica Ceca 21
BE - Belgio 13
NL - Olanda 13
PL - Polonia 13
UZ - Uzbekistan 11
GR - Grecia 9
AU - Australia 7
CA - Canada 7
LB - Libano 7
RO - Romania 7
EU - Europa 5
MX - Messico 5
IN - India 4
JP - Giappone 4
KR - Corea 4
PH - Filippine 4
BR - Brasile 2
EE - Estonia 2
AR - Argentina 1
BD - Bangladesh 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
HU - Ungheria 1
ID - Indonesia 1
IM - Isola di Man 1
LU - Lussemburgo 1
MY - Malesia 1
RS - Serbia 1
Totale 9.422
Salva come PNG Salva come JPEG
Città #
Dublin 830
Chandler 772
Jacksonville 581
San Mateo 537
Medford 248
Hong Kong 247
Princeton 246
Altamura 206
Dong Ket 192
Wilmington 184
Singapore 177
Lawrence 145
Andover 120
Izmir 112
Ann Arbor 104
Des Moines 101
Perugia 97
Saint Petersburg 78
Beijing 49
Boardman 47
Norwalk 43
Helsinki 39
New York 39
Los Angeles 37
Woodbridge 36
Ashburn 33
Falls Church 24
Fremont 24
Shanghai 23
Rome 22
Amelia 17
San Paolo di Civitate 16
Moscow 15
Brussels 13
Brno 11
Auburn Hills 10
Bologna 10
Den Haag 9
Vienna 9
Chicago 8
Redmond 8
Frankfurt Am Main 7
Terni 7
Milan 6
Bucu 5
Olomouc 5
Redwood City 5
Cebu City 4
Lausanne 4
Salerno 4
San Diego 4
Casalbordino 3
Edinburgh 3
Foligno 3
Hangzhou 3
Houston 3
Melbourne 3
Occhiobello 3
Seoul 3
Surrey 3
Tappahannock 3
Torino 3
Treviso 3
Amsterdam 2
Brendola 2
Cambridge 2
Hanover 2
Hyderabad 2
Kiev 2
Leipzig 2
León 2
Manassas 2
Nürnberg 2
Osoppo 2
Padova 2
Perth 2
Pisa 2
Plaistow 2
Plymouth 2
San Giuliano Terme 2
Segrate 2
Selargius 2
Spring 2
Swansea 2
Tallinn 2
Torre Del Greco 2
Varese 2
Abidjan 1
Ariano nel Polesine 1
Athens 1
Belen de Escobar 1
Belgrade 1
Belo Horizonte 1
Berlin 1
Brisbane 1
Bucharest 1
Budapest 1
Calvisano 1
Castel Maggiore 1
Cepagatti 1
Totale 5.667
Salva come PNG Salva come JPEG
Nome #
Ipoglicemia da iperinsulinismo organico: un caso di nesidioblastosi dell’adulto. 141
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 113
Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. 102
Adrenaline vs glucagon in the primacy of glucose counterregulation 97
Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. 92
Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin. 88
Alternative routes of insulin delivery 88
Intensive insulin treatment in diabetic children 74
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 74
Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus 73
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 71
Nocturnal blood glucose control in type I diabetes mellitus. 70
Adrenergic activity and glycometabolic compensation in patients with diabetes mellitus]. 69
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment. 68
Aspetti attuali del Diabete Mellito 2002 65
Impiego dell’analogo dell’insulina glargine in una paziente affetta da diabete di tipo 2 con grave resistenza insulinica. 63
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs 63
A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. 63
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 63
Insulin treatment and its complications 62
Clinical strategies for controlling peaks and valleys: type 1 diabetes 62
Uso dell’analogo ad azione rapida lispro con l’analogo ad azione ritardo glargine nel trattamento intensivo del T1DM 62
Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. 62
Adrenergic mechanisms do not contribute to glucose counterregulation during acute insulin-induced hypoglycaemia in normal man. 62
18. Insulin required for prandial ghrelin suppression in humans 61
The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity 61
Establishing the deficiency of glucagon response to hypoglycemia in humans 61
Treatment and prevention of hypoglycemia and its unawareness in Type 1 diabetes mellitus 60
Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. 60
[Behavior of plasma androgens in cases of adrenal pathology]. 60
COMPARISON OF VILDAGLIPTIN AND PIOGLITAZONE IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH METFORMIN. 59
Glucose variability and complications. 59
Rational use of insulin analogues in the treatment of Type 1 diabetes mellitus 58
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 58
Glucose variability and complications. 57
Insulins today and beyond 57
Analysis of short-term changes in reversibly and irreversibly glycosylated haemoglobin A I: Relevance to diabetes mellitus 57
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 57
La resistenza insulinica nel diabete mellito di tipo I Effetti della terapia insulinica intensiva 57
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). 57
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia 56
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 56
Contribution of amino acids and insulin to protein anabolism during meal absorption. 56
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans. 56
Hypoglycemia 55
Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus 55
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. 53
Counterregulatory hormone and symptom responses to insulin-induced hypoglycaemia in the postprandial state in humans 52
Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. 52
A novel surrogate index for hepatic insulin resistance. 52
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial 51
Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans 51
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 51
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 51
Il nuovo analogo dell’insulina ad azione ritardata glargine: caratteristiche ed uso terapeutico nel diabete mellito 50
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 50
Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. 50
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro 50
The effect of menopause on carotid artery remodelling, insulin sensitivity, and plasma adiponectin in healthy women. 49
null 49
Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus 49
Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women. 48
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 48
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 48
A case of neoplastic hemorrhagic pericarditis. 48
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 48
Terapia insulinica moderna 47
Insulin treatment in type 1 diabetes. 47
Intensive replacement of basal insulin in patients with Type 1 diabetes mellitus given rapid-acting insulin analogue at meal-time: a three-month comparison between administration of NPH four times daily and glargine insulin at dinner or bedtime. 47
Opinioni a confronto: quando e come usare il microinfusore rispetto alla terapia insulinica multi-iniettiva nella terapia intensiva del diabete mellito tipo 1. 47
Hyperglycemia alters the physico-chemical properties of proteins in erythrocyte membranes of diabetic patients 47
Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. 47
Glucagon: the effects of its excess and deficiency on insulin action 46
Lack of glucagon response in glucose counter-regulation in type 1 (insulin-dependent) diabetics: absence of recovery after prolonged optimal insulin therapy 46
Responses to hypoglycemia in diabetic autonomic neuropathy. 46
Insulin is required for prandial ghrelin suppression in humans 46
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. 45
Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. 45
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people. 45
THE CATECHOLAMINE CONTRIBUTION TO HYPOGLYCEMIA IN IDDMDiabetes 45
Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus 44
Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. 44
[Effects of circulating anti-insulin antibodies on the kinetics of injected insulin in type I diabetes mellitus]. 43
Chloroquine reduces whole body proteolysis in humans 43
Kinetic behaviour of the glucose-hemoglobin labile adduct in normal and diabetic erythrocytes. 43
Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment statisfaction 43
Erythrocyte concentration of glycolytic phosphorylated intermediates and adenosine nucleotides in subjects with diabetes mellitus. 43
Future options for insulin therapy 42
Quando “i conti non tornano” (Caso clinico) G It Diabetol Metab 26:172-175 42
Insulin therapy and hypoglycemia: the size of the problem 42
Hyperglycemia, Both Chronic and in Short-Term Peaks, Results in Rapid Increase of Expression of Monocyte Inducible Cyclooxygenase (COX-2) in Subjects with T2DM 42
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 42
Beyond the era of NPH insulin - Long-acting insulin analogs: chemistry, comparative pharmacology and clinical application. 41
Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial 41
Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans. 41
Somogyi and dawn phenomena: mechanisms 41
Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. 41
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 41
Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning 40
Optimizing the replacement of basal insulin in Type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. 40
Totale 5.605
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.801
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.801
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020909 58 20 158 8 149 46 159 16 164 45 12 74
2020/20212.154 4 168 90 158 629 163 158 15 264 74 193 238
2021/20221.843 42 332 46 130 52 16 10 642 18 52 210 293
2022/20232.836 259 486 38 201 204 346 6 117 1.064 7 85 23
2023/20241.090 72 122 50 19 15 10 208 24 101 52 216 201
2024/202516 16 0 0 0 0 0 0 0 0 0 0 0
Totale 9.827